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Brief description of the novelty and impact of the paper: A limitation to the success of single HER-targeting 
mAbs is the development of acquired resistance through mechanisms such as switch in receptor 
dependencies and altered receptor dimerization patterns. Here we demonstrate that Pan-HER, a novel mAb 
mixture simultaneously targeting EGFR, HER2, and HER3 lowers basal EGFR homo- and 
heterodimerization levels and inhibits ligand-induced changes in EGFR dimerization, demonstrating the 
potential of Pan-HER to circumvent such resistances.  
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Abstract 
The human epidermal growth factor receptor (HER)-family is involved in development of many epithelial 
cancers. Therefore, HER-family members constitute important targets for anti-cancer therapeutics such as 
monoclonal antibodies (mAbs). A limitation to the success of single HER-targeting mAbs is development of 
acquired resistance through mechanisms such as alterated receptor dimerization patterns and dependencies. 
Pan-HER is a mixture of six mAbs simultaneously targeting epidermal growth factor receptor (EGFR), 
HER2, and HER3 with two mAbs against each receptor. Pan-HER has previously demonstrated broader 
efficacy than targeting single or dual receptor combinations also in resistant settings. In light of this broad 
efficacy, we decided to investigate the effect of Pan-HER compared with single HER-targeting with single 
and dual mAbs on HER-family cross-talk and dimerization focusing on EGFR. The effect of Pan-HER on 
cell proliferation and HER-family receptor degradation was superior to treatment with single mAbs targeting 
either single receptor, and similar to targeting a single receptor with two non-overlapping antibodies. 
Furthermore, changes in EGFR-dimerization patterns after treatment with Pan-HER were investigated by in 
situ proximity ligation assay and co-immunoprecipitation, demonstrating that Pan-HER and the EGFR-
targeting mAb mixture efficiently down-regulate basal EGFR homo- and heterodimerization in two tested 
cell lines, whereas single mAbs had limited effects. Pan-HER and the EGFR-targeting mAb mixture also 
blocked EGF-binding and thereby ligand-induced changes in EGFR-dimerization levels. These results 
suggest that Pan-HER reduces the cellular capability to switch HER-dependency and dimerization pattern in 
response to treatment and thus hold promise for future clinical development of Pan-HER in resistant settings. 
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Introduction 
The human epidermal growth factor receptor (HER)-family is one of 20 subfamilies of human receptor 
tyrosine kinases (RTKs) comprising epidermal growth factor receptor (EGFR) (ErbB1), HER2 (ErbB2), 
HER3 (ErbB3), and HER4 (ErbB4). Many cancers are driven by HER-family dependencies where signal 
transduction pathways of the HER-family receptors are deregulated leading to increased proliferation and 
escape from apoptosis [1–3].  
EGFR is one of the most studied HER-family receptors and a recognized key oncogenic driver in many 
epithelial cancers. Upon activation by ligands such as epidermal growth factor (EGF) two monomeric 
EGFRs dimerize to form an actively signaling complex. EGFR also associates in heterodimers with other 
RTKs, such as HER2 and HER3 [2], [4]. It is well known that heterodimerization of and cross-talk between 
HER-family receptors play an important role in primary and acquired resistance to targeted treatments [5–7]. 
Furthermore, accumulating evidence suggests that dimerization is not always ligand-dependent and that 
when EGFR is overexpressed, a significant fraction of receptors exists in preformed homo- and heterodimers 
[8–10]. Also, there is a correlation between overexpression of EGFR and activation of downstream signaling 
molecules such as AKT and ERK1/2 [11], suggesting that the preformed dimers are actively signaling. This 
phenomenon is also known for other RTKs such as HER2 and MET [12], [13]. 
As mentioned above, EGFR forms heterodimers with both HER2 and HER3, with HER2 being the preferred 
heterodimerization partner for the other HER-family members [2], [14], [15]. Furthermore, no ligand for 
HER2 has been identified and HER2 activation therefore requires heterodimerization with other receptors to 
become ligand-activated. HER3 is activated upon binding of heregulin (neuregulin), but since HER3 
contains an impaired tyrosine kinase, the receptor can most potently signal in heterodimers [16], [17]. Upon 
EGF-induced activation of EGFR homodimers, the receptors undergo fast internalization and degradation 
compared to ligand-induced internalization of other HER-family members [18–20]. In this regard, it has been 
shown that EGFR in heterodimers with HER2 or HER3, and overexpression of for instance HER2 results in 
prolonged and enhanced signaling, through increased recycling and internalization compared to EGFR in  
homodimers [21–23].  
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Several agents targeting HER-family receptors including tyrosine kinase inhibitors and monoclonal 
antibodies (mAbs) are clinically approved for treatment of various cancers. Five therapeutic mAbs targeting 
HER-family receptors are currently on the market; cetuximab (Erbitux®), panitumumab (Vectibix®), and 
nimotuzumab (various brandnames) targeting EGFR and trastuzumab (Herceptin
®
) and pertuzumab 
(Perjeta
®
) targeting HER2 [24]. While no HER3 targeting antibodies have yet reached clinical approval, the 
fully human mAb MM-121 (Seribantumab) is currently being evaluated in late clinical trials [25], [26].  
However, acquired resistance towards single receptor targeting treatments greatly limits the therapeutic 
potential of single HER-targeting therapies. Mechanisms of resistance toward single HER-family targeting 
mAbs include receptor mutations, increased ligand production, compensatory receptor up-regulation, switch 
in receptor dependency, and increased receptor cross-interactions by heterodimerization [6]. Specifically 
with regards to cetuximab resistance, mechanisms such as increased EGFR expression and co-activation of 
other RTKs through heterodimerization with EGFR has been observed [27]. Resistance mechanisms to 
trastuzumab treatment also include increased EGFR expression, activation of EGFR-HER2 heterodimers, 
and increased levels of EGFR and HER3 ligands [28], [29].  
It has been shown that mixtures of mAbs targeting a single HER-family member have superior inhibitory 
efficacy when it comes to cell growth, down-regulation of single receptors and heterodimers, and decreased 
downstream signaling compared to a single mAb targeting the same receptor [30–34]. Furthermore, it has 
been shown that resistance toward single targeting mAbs as a result of switch in receptor dependency and 
receptor heterodimerization can be overcome by targeting the activated receptor [27]. For example 
cetuximab resistances, due to ligand-induced activation of HER3 and prosurvival pathways, can be abrogated 
by treatment with MM-121 or dual EGFR-HER2 targeting [26], [35], [36]. Also, increased expression of 
HER3 due to pertuzumab treatment can be abrogated by targeting HER3 [37]. Together, this indicates a 
strong rationale for combinatorial targeting of HER-family receptors with mAb mixtures to circumvent 
resistance, via heterodimerization and compensatory receptor up-regulation, toward single HER-family 
targeting mAbs.  
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Pan-HER is a mixture of six mAbs comprising a pair of mAbs targeting non-overlapping epitopes of each of 
EGFR, HER2, and HER3 in a balanced ratio. Pan-HER was recently reported to demonstrate superiority to 
single mAbs targeting HER-family receptors delaying both primary and acquired resistance due to tumor 
heterogeneity and plasticity [38].  
Here we investigated HER-family dimerization patterns upon treatment with single HER-targeting mAbs, 
mixtures of two mAbs targeting a single receptor, and Pan-HER in HER-dependent cell lines. The results 
show that Pan-HER and the single targeting mAb mixtures decrease proliferation, downstream signaling, and 
total receptor levels of EGFR, HER2, and HER3 more effectively than single mAbs, but also that 
multitargeting of all three receptors with Pan-HER is essential to have the broadest efficacy. Furthermore, 
Pan-HER and the single targeting mAb mixtures lower basal EGFR homo- and heterodimerization levels in 
absence of ligand proportionally to decreased receptor levels and inhibits EGF-induced changes in EGFR 
dimerization by blocking EGF binding, whereas the single mAbs have almost no effect. However, 
simultanous targeting of all three HER-family receptors by treatment with Pan-HER, may provide a more 
efficacious therapeutic strategy by means of multiple receptor targeting in HER dependent tumors. 
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Materials and Methods 
Cell lines 
PK-1 and OVCAR-8 cell lines were obtained from RIKEN Cell Bank and National Cancer Institute, 
respectively and grown for limited numbers of passages in RPMI1640+10% Fetal Bovine Serum (FBS)+1% 
Penicillin/Streptomycin (Life Technologies) at 37°C, 5% CO2, and serum starved 24-48 hours prior to 
experiments. All cell lines were routinely tested for mycoplasma infection and cell line authenticity was 
documented by Human Cell Line Authentication (LGC Standards). 
Therapeutic antibodies 
The six antibodies used for the 2-mAb mixtures and Pan-HER were generated as described elsewhere [38]. 
Cetuximab (Erbitux
®
)  and trastuzumab (Herceptin
®
) were obtained from Merck KGaA and Roche, 
respectively. Analogues of pertuzumab and MM-121 were generated in house and tested, along with a mAb 
binding non-human IgG used as negative control, as previously specified [34], [38]. 
Detection of cell surface expressed receptors 
Flow cytometry was used to quantify surface expressions of EGFR, HER2, and HER3 in cancer cell lines 
using Quantum Simply Cellular beads (Bangs Laboratories) conjugated with capture antibodies (as detailed 
below). The output Antibody Binding Capacity (ABC=ABCdetection antibody-ABCisotype control) of each cell line 
correlates with the number of receptors on the cell surface. Cells were dissociated using Cell Dissociation 
Reagent (Life Technologies) and filtrated in 70µm Cell Strainers (BD Biosciences). 1.0x10
5
 cells per well 
were washed and stained using anti-EGFR, anti-HER2, and anti-HER3 detection and isotype control 
antibodies (Abcam, clone #: ICR10 and RTK2758 and R&D Systems, clone #: 191924, 133303, 66223, and 
11711), prior to analysis on FACSVerse Flow cytometer (BD Biosciences) with Kaluza flow analysis 
software (Beckman Coulter).  
Proliferation assay by live cell imaging 
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PK-1 and OVCAR-8 cells were plated in medium containing 0.5% FBS and 50 µg/mL antibody and 
proliferation was followed for 160 hours using IncuCyte ZOOM (Essen Bioscience) to obtain pictures every 
fourth hour. IncuCyte ZOOM 2015A software (Essen Bioscience) was used for data analysis.  
Cell treatment and harvest of lysates 
Cells were grown to approximately 80% confluency prior to antibody treatment for 24 hours. 15 minutes 
prior to harvest, cells were stimulated with 1 nM EGF (R&D Systems) or left unstimulated. Ice cold 1x Lysis 
Buffer (Cell Signaling Technology) containing Protease Inhibitor Cocktail kit (Thermo Scientific) and 
Phosphatase Inhibitor Cocktail set II (Calbiochem) was added, cells harvested with a cell scraper, and 
cleared by centrifugation at 4°C. Protein concentration measurements were carried out using Pierce BCA 
Protein Assay kit (Thermo Scientific) prior to co-immunoprecipitation (Co-IP) and/or Western blot analysis. 
Western blot analysis 
Effects of antibody treatments on total and phospho-protein levels were investigated by Western blot 
analysis. Primary antibodies: Rabbbit anti-EGFR, rabbit anti-HER2, rabbit anti-HER3 (Cell Signaling 
Technology, clone #: D38B1, 29D8, and D22C5), mouse anti-HER3 (Millipore, clone #: 2F12), rabbit anti-
AKT, rabbit anti-pAKT (Ser473), rabbit anti-ERK1/2, rabbit anti-pERK1/2 (Thr202/204), and rabbit anti-β-
actin (Cell Signaling Technology, clone #: D9E, D13.14.4E, and 13E5) diluted in Odyssey Blocking Buffer 
(LI-COR Biosciences) were used for detection, and membranes were scanned on Odyssey Scanner (LI-COR 
Biosciences) using Odyssey IR Imaging System (LI-COR Biosciences). 
Duolink in situ proximity ligation assay 
Duolink proximity ligation assay (PLA) was used for detection, quantification, and visualization of EGFR 
homo- and heterodimers, using EGFR, HER2, and HER3 detection antibodies generated as described 
elsewhere [38]. PLUS and MINUS PLA probes were made from these antibodies according to the 
manufacturer’s instructions (Olink Bioscience). 5,000 cells/well were plated in 2% FBS 48-72 hours prior to 
measurements. 24 hours prior to measurements, cells were treated with 40 µg/mL Pan-HER, cetuximab, 
trastuzumab, pertuzumab, MM-121 or negative control mAb. For ligand stimulation, cells were incubated 
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with 1 nM EGF for 15 minutes at 37°C, prior to fixation with 3.7 % formaldehyde for 10 minutes and 
permeabilization with 0.1 % Triton X-100 for 5 minutes. Cells were blocked and probed with anti-EGFR-, 
anti-HER2-, and anti-HER3-PLA probes, added in PLUS-MINUS pairs, followed by ligation, rolling circle 
amplification, and washing. Cytosols and nuclei were stained with Cell Mask Blue and Hoechst (Life 
Technologies) before confocal microscopy analysis using Opera high content screening system (Perkin 
Elmer, ver. 2.0.1) for visualizing PLA signals at 40X magnification and Acapella high content imaging and 
analysis software (Perkin Elmer, ver. 2.6) for quantifying PLA signals and cells. The number of positive 
spots/cell was calculated based on analysis of 15 pictures in each of three replicate wells. Statistical 
significance was calculated using Student’s t-test. In the experiment with EGF stimulation, the number of 
PLA signals/cell was normalized to the total level of EGFR determined by Western blot analysis in order to 
exclude the effect of degradation due to the antibody treatments.  
Detection of labelled EGF to PK-1 cells 
5,000 PK-1 cells/well were plated in 2% FBS 48h prior to 30minutes of Pan-HER treatment and stimulation 
with 2ug/mL Alexa-647 labelled EGF (Thermo Fisher Scientifc) for 3min at 4°C to limit ligand-induced 
internalization. Cells were fixed, permeabilized, and blocked as described above prior to staining with FITC-
labelled anti-EGFR antibody (Abcam, Clone ICR10) for 1h. Cytosols and nuclei were stained with Cell 
Mask Blue and Hoechst (Life Technologies) followed by confocal microscopy analysis. 
Co-Immunoprecipitation 
Indirect Co-IP with streptavidin-conjugated beads was performed according to manufacturers instructions 
(Thermo Scientific), using 2 mg total protein from each lysate sample and biotinylated capture or isotype 
control antibody (R&D Systems and Cell Signaling Technology, clone MOPC-21), and incubated for two 
hours with tilting at room temperature. 0.5 mg beads per sample were prewashed prior to incubation with 
Ab-antigen samples for one hour with tilting at room temperature. Finally, samples were washed, incubated 
in low pH Elution Buffer for 5 minutes at room temperature, and subjected to Western blot analysis.
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Results 
Selection and characterization of HER-dependent cancer cell lines for studying EGFR dimerization 
Seeking to evaluate the effect of Pan-HER on EGFR homo- and heterodimerization, we aimed to identify 
EGFR high expressing cancer cell lines with sensitivity to more than one HER-targeted therapeutic mAb, 
because such models could be expected to be driven by HER-family heterodimerization.  
15 cancer cell lines sensitive to Pan-HER treatment [38] (and data not shown) were screened for total and 
surface expression levels of EGFR, HER2, and HER3 by Western blot analysis and flow cytometry, 
respectively. The 15 cell lines displayed highly varying receptor levels, even though the majority expressed 
rather high levels of EGFR (Fig. 1A). Based on the protein levels in Fig. 1A and a previous screen of HER-
dependence [38], two cell lines (PK-1 and OVCAR-8) were selected for studying sensitivity to single HER-
targeting and Pan-HER. Both PK-1 and OVCAR-8 expressed very high cell surface levels of EGFR and both 
cell lines expressed low but detectable levels of HER2 (Fig. 1B). Furthermore, PK-1 expressed a very low 
level of HER3, while OVCAR-8 was chosen because it expressed the highest level of HER3 of all the 
analyzed cell lines.  
Next, the cell line sensitivity to single HER-targeting mAbs and Pan-HER was investigated by live cell 
imaging. As shown in Fig. 2A, both PK-1 and OVCAR-8 demonstrated varying sensitivity to single HER-
targeting mAbs, mAb mixtures, and Pan-HER. Pan-HER most effectively inhibited the proliferation of PK-1 
closely followed by both the HER3-targeting mAb mixture and MM-121. Whereas in OVCAR-8, Pan-HER, 
MM-121, and the EGFR- and HER3-targeting mAb mixtures inhibited the proliferation to the same extent. 
This effect of Pan-HER (Suppl. Fig. 1) and the other HER-targeting mAbs demonstrates that targeting of the 
receptors with more than one antibody effectively decreases proliferation, and that more than one HER-
family member contributes to the growth of both cell lines, which were therefore considered suitable in vitro 
models for studying alterations in HER-dimerization patterns upon Pan-HER treatment.   
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Treatment with Pan-HER has previously been reported to cause simultaneous down-regulation of EGFR, 
HER2, and HER3 [38], so in order to evaluate effect on downstream signaling, the effect of Pan-HER and 
single targeting mAbs on total HER-family receptor levels and phosphorylation levels of the major 
downstream signaling molecules AKT and ERK1/2 was investigated in both cell lines. The mixtures 
targeting single receptors caused down-modulation of their respective target, while Pan-HER simultaneously 
reduced the protein levels of all three receptors (Fig. 2B). Cetuximab and pertuzumab treatment did not alter 
the receptor levels, however, trastuzumab and MM-121 were able to decrease the HER2 and HER3 levels, 
respectively in both cell lines but not to the same extent as Pan-HER and the HER2- and HER3-targeting 
mixtures. Furthermore, signs of compensatory up-regulation of EGFR, HER2 or HER3 were observed upon 
single targeting treatments. For example the HER2- and HER3-targeting mAb mixtures slightly increased 
EGFR levels in PK-1, MM-121 increased HER2 levels in both cell lines, and pertuzumab treatment 
increased HER3 levels in OVCAR-8. In contrast, Pan-HER effectively decreased the expression of all three 
receptors, thus preventing compensatory up-regulation. Furthermore, the level of pAKT in both cell lines 
was decreased upon HER3-targeting (MM-121, HER3 and Pan-HER). In PK-1 pERK1/2 was slightly 
decreased by cetuximab and more abundantly by the EGFR-targeting mAb mixture and Pan-HER. In 
OVCAR-8 MM-121, the HER3-targeting mAb mixture, and Pan-HER all decreased the pERK1/2 level, 
whereas, both the EGFR- and HER2–targeting mAb mixture slightly increased pERK1/2 levels. Neither total 
AKT or ERK1/2 levels were altered upon any of the treatments.   
In summary, both PK-1 and OVCAR-8 exhibited sensitivity to targeting of both single and multiple HER-
family receptors, suggesting that HER-family heterodimerization might play a growth promoting role in both 
cell lines. The two cells lines were used to study changes in EGFR dimerization in response to treatment with 
single HER-targeting mAbs, mixtures, and Pan-HER. 
Pan-HER down-regulates basal EGFR homodimer levels in PK-1 and OVCAR-8 cells  
PLA was applied to investigate EGFR dimerization in cells treated with single HER-targeting mAbs, 
mixtures or Pan-HER. Since PLA is an antibody based detection method, it is essential that the detection 
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antibodies and the therapeutic antibodies bind non-overlapping epitopes. Previous epitope binning and 
binding competition studies have confirmed that the epitopes of the detection antibodies against EGFR, 
HER2, and HER3 did not overlap with the therapeutic mAbs (cetuximab, trastuzumab, and pertuzumab) and 
the mAbs comprising Pan-HER, and that the detection antibodies had single target specificity with regard to 
binding and cross-reactivity to EGFR, HER2, and HER3 [34], [39], [40] (Suppl. Fig. 2).  
EGFR is known to associate in preformed homodimers in absence of ligand [8–10] and since PK-1 and 
OVCAR-8 both express high levels of EGFR, the level of EGFR homodimers in these cell lines was 
investigated using PLA. In contrast to cetuximab, which did not alter the EGFR homodimer level, both the 
EGFR-targeting mAb mixture and Pan-HER significantly decreased the basal EGFR homodimer level in 
both PK-1 and OVCAR-8 upon 24 hours of treatment (p< 0.001, p< 0.01, and p< 0.05) (Fig. 3). These results 
correlate with the decrease in total EGFR levels detected by Western blot analysis upon treatment with the 
EGFR-targeting mAb mixture and Pan-HER but not upon cetuximab treatment (Fig. 2B). The decrease in 
homodimers is therefore likely due to receptor degradation. This is further supported by the fact that no 
significant receptor degradation and no change in basal EGFR homodimer and EGFR-HER2 heterodimer 
levels were observed upon one hour treatments (data not shown). Furthermore, it could be speculated that 
treatment with single mAbs targeting other HER-family members could push the dimerization balance 
towards an increase in EGFR homodimers. However, treatment with trastuzumab, pertuzumab, and MM-121 
did not affect EGFR homodimerization levels (data not shown).   
Pan-HER down-regulates basal EGFR heterodimer levels in PK-1 and OVCAR-8 cells  
EGFR has been shown to associate in preformed heterodimers with HER2 or HER3 [8], [9], and therefore 
the basal levels of HER-family heterodimers in PK-1 and OVCAR-8 was also investigated after treatment 
(Fig. 4). Collectively, the results in Fig. 4 demonstrate that the single mAbs had very little effect and did not 
alter the EGFR heterodimer levels in PK-1 and OVCAR-8 cells. On the other hand, Pan-HER and some of 
the single HER-targeting mAb mixtures effectively decreased both basal EGFR-HER2 and EGFR-HER3 
heterodimer levels in both PK-1 and OVCAR-8, most likely through receptor degradation. However, while 
Page 12 of 30
John Wiley & Sons, Inc.
International Journal of Cancer
This article is protected by copyright. All rights reserved.
13 
 
the EGFR-targeting mAb mixture reduced both EGFR-HER2 and EGFR-HER3 levels in both cell lines the 
HER2- and HER3-targeting mAb mixtures did not significantly alter the EGFR-HER2 and EGFR-HER3 
dimer levels in OVCAR-8, respectively, despite the fact that the receptors are being degraded (Fig. 2B). 
Furthermore, trastuzumab and MM-121 treatments resulted in degradation of HER2 in PK-1 and OVCAR-8 
cells and HER3 in OVCAR-8 cells, respectively (Fig. 2B), but neither treatment altered the EGFR-HER2 
and EGFR-HER3 heterodimer levels (Fig. 4). This indicates that targeting of more than one receptor in the 
dimer is more likely to succesfully down-regulate preformed HER-family dimer levels, and that Pan-HER 
has the potential to prevent cancer cells from evading treatment by switching HER-family dependency.      
Pan-HER prevents EGF-induced changes in EGFR dimerization in PK-1 cells 
Increased EGFR expression, increased EGFR-HER2 heterodimerization, and increased levels of EGF all 
play a role in acquired resistance toward cetuximab and trastuzumab [27], [28]. Therefore, it was of interest 
to investigate the effect of treatment on ligand stimulation and ligand-induced HER-family dimerizations. 
This was done by investigating the ability of Pan-HER to interfere with EGF binding to EGFR and by 
studying the EGFR homo- and EGFR-HER2 heterodimerization levels upon treatment with single targeting 
mAbs, mixtures, and Pan-HER for 24 hours followed by 15 minutes of EGF stimulation in PK-1 cells. The 
PLA signals were normalized to total EGFR protein levels as determined by western blot analyies after 24 
hours of treatment, to exclude the effect of protein degradation on the PLA dimerization signal.  
In Figure 5A, the immunofluorescence stainings showed that Pan-HER effectively blocks EGF binding to 
EGFR, thereby possibly preventing EGF from inducing changes in EGFR dimerization levels (Fig. 5A). 
Furthermore, using PLA it was shown that 15 minutes of EGF stimulation lowered the basal EGFR dimer 
levels in PK-1, likely due to ligand-induced receptor activation and internalization resulting in decreased 
detection by PLA. However, cetuximab, the EGFR-targeting mAb mixture, and Pan-HER maintained EGFR 
dimer levels at baseline levels regardless of EGF stimulation (Fig. 5B) supporting the result in Figure 5A, 
that the EGFR-targeting mAbs of Pan-HER interfer with EGF-induced EGFR dimer dynamics.  On the other 
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hand, none of the other single mAbs inhibited the EGF-induced decrease in the dimer levels, and neither did 
the HER2-targeting mAb mixture shown by an even larger decrease in the detected dimer level (Fig. 5B).       
To confirm and support these results, Co-IP for detection of EGFR homo- and EGFR-HER2 heterodimers 
was performed on whole cell PK-1 lysates. As shown in Fig. 5C, untreated cells stimulated for 15 minutes 
with EGF resulted in an increase in the EGFR dimer level in PK-1. However, Pan-HER treatment resulted in 
both a decrease in basal EGFR homodimer level and also triggered reduction of homo- and heterodimer 
levels upon EGF stimulation. Finally, as shown in Fig. 5D, Pan-HER was also able to decrease pEGFR 
levels and phosphorylation of the downstream signaling molecules AKT and ERK1/2 when cells were 
stimulated for 15 minutes with EGF, indicating that Pan-HER inhibit EGF-induced activation of EGFR 
dimers. Together, these results demonstrate that Pan-HER effectively reduces the level of both preformed 
EGFR dimers and ligand-induced dimerization and activation of EGFR. 
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Discussion 
Previous studies have shown that increased EGFR expression and activation of HER2 and HER3 through 
heterodimerization with EGFR are involved in acquired resistance towards cetuximab and trastuzumab [27], 
[28]. Here we demonstrate the potential of the antibody mixture Pan-HER to overcome such resistance, since 
Pan-HER was found to down-regulate both total HER-family receptor levels, basal EGFR homo- and 
heterodimer levels, and prevent EGF-induced changes in EGFR dimerization in two EGFR overexpressing 
cell lines.  
Pan-HER and the single HER-targeting mAb mixtures were shown to decrease the total receptor levels more 
effectively than the single mAbs in both PK-1 and OVCAR-8 cells (Fig. 2B). It has previously been shown 
that two antibodies targeting a single HER-family receptor more potently down-regulate the receptors than a 
single mAb targeting the same receptor [30–34], [38]. In the current studies all treatments were performed at 
equal total antibody concentrations, meaning that since Pan-HER contains two antibodies targeting each of 
EGFR, HER2, and HER3, the concentration of antibodies targeting each receptor is 1/3 of the concentration 
of the single mAbs and the single HER-targeting mAb mixtures. Thus, the superior receptor down-regulating 
effect of Pan-HER compared to the single targeting mAbs and mixtures underlines the added benefit of 
combining mAbs against multiple receptors. A possible explanation for this synergy is that targeting with 
multiple mAbs results in crosslinking of receptors inducing efficient receptor down-regulation even when 
associated in preformed dimers, and that the effect of crosslinking is greater when multiple receptors are 
targeted [31]. Furthermore, compensatory receptor up-regulation was observed upon treatment with some of 
the single receptor targeting mAbs and mixtures (Fig. 2B), while the ability of Pan-HER to simultaneously 
decrease the level of EGFR, HER2, and HER3 prevents compensatory HER-family receptor up-regulation as 
a resistance mechanism. 
The effect of mAb mixtures targeting more than one HER-family receptor on heterodimerization has only 
received limited focus so far [32], [41], [42]. Nevertheless, the effect of Pan-HER on HER-family 
dimerization shown here is consistent with previously reported effects of the combined targeting of two 
receptors. For example the effect of trastuzumab in combination with pertuzumab on down-regulating 
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EGFR-HER2 heterodimerization in the presence of EGF [32] is consistent with the effect of Pan-HER shown 
in Fig. 5, and the ability of cetuximab plus trastuzumab to down-regulate basal EGFR-HER2 heterodimers is 
consistent with the effect of Pan-HER shown in Fig. 4 [41], [42]. Common for these results is also that the 
single mAbs have almost no effect by themselves compared to the multitargeting when it comes to altering 
the HER-family dimerization levels.  
The preformed EGFR homo- and heterodimers may drive resistance development in two ways. First, the 
preformed dimers may be able to potently signal in a ligand-independent manner when overexpressed, as is 
the case with HER2 and MET overexpression [12], [13], or secondly they might be positioned in dormant 
receptor complexes which will be activated upon increased ligand production, which is also a documented 
resistance mechanism [26], [28], [43]. In both cases, the ability of Pan-HER (but not the single mAbs) to 
remove preformed EGFR homo- and heterodimers, might reduce the risk of development of such resistances.  
Phosphorylation of both AKT and ERK1/2 was down-regulated upon treatment with Pan-HER (Fig. 2B), 
indicating inhibition of both signaling pathways. In contrast, the effect of the single mAbs on downstream 
signaling varied in the two cell lines. The pAKT level was decreased upon treatment with HER3-targeting in 
both cell lines, correlating with the fact that HER3 activates AKT. Furthermore, the pERK1/2 level was 
decreased by treatment with EGFR-targeting in PK-1 and HER3-targeting in OVCAR-8, the latter indicating 
that signaling through EGFR-HER3 heterodimers is inhibited, decreasing the activation of ERK1/2 [2]. Even 
though trastuzumab treatment resulted in down-regulation of total HER2 levels in both cell lines, neither 
pAKT nor pERK1/2 levels were altered (Fig. 2).  
Pertuzumab has previously been shown to block HRG-induced dimerization of HER2 and HER3 and also 
down-regulate basal HER2-HER3 dimer levels in HER2-high expressing cancer cells [44], [45]. 
Furthermore, pertuzumab has been shown to disrupt EGFR-HER2 heterodimers and push the dimer 
distribution toward EGFR homodimerization when stimulated with EGF [46], [47]. Surprisingly, we found 
that pertuzumab was neither able to down-regulate basal EGFR-HER2 dimer levels, nor prevent EGF-
induced down-regulation of EGFR-HER2 heterodimers using PLA. However, this might be explained by the 
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relatively low HER2 expression in these two cell lines, as pertuzumab might have a different effect on dimer 
distribution in HER2 overexpressing and/or amplified cell lines. Furthermore, cetuximab has been shown by 
others to slightly reduce both basal and EGF-induced EGFR-HER2 dimerization [42]. However, only the 
ability of cetuximab to block EGF-induced down-regulation of EGFR dimers was observed in this study. 
This is in line with the finding that cetuximab partially blocks the EGF binding site and locks EGFR in its 
closed conformation [48].  
The effect of EGF on EGFR dimerization was investigated using two different assays: PLA and Co-IP. 
Using PLA, 15 minutes of EGF stimulation resulted in a decrease in EGFR dimer levels after normalization 
to total EGFR levels, indicating rapid internalization of EGFR dimers in line with previous reports by others 
[18–20]. Co-IP-based analysis of the effect of EGF on whole cell EGFR-dimer levels demonstrated that 15 
minutes of EGF stimulation resulted in an increase in EGFR homo and heterodimer levels, correlating with 
previous use of Co-IP  to detect EGFR-HER2 dimers upon EGF stimulation [47]. This difference in the 
effect of EGF might be explained by differences in the two assays. For example, if PLA primarily detects 
dimers at the cell surface level, the loss of EGFR dimer signals would be explained by internalization but not 
degradation of the dimers, which is expected to take more than 15 minutes. This explains why an increase in 
EGFR dimer levels was observed using Co-IP, which detects both intra- and extracellular dimer complexes. 
Therefore, we decided to normalize the EGFR dimer levels with and without EGF stimulation to the total 
EGFR levels, to study the effect of antibody treatments on EGFR dimerization dynamics while excluding the 
effect of receptor degradation. This showed that, Pan-HER, the EGFR targeting mAb mixture, and 
cetuximab were all able to prevent the EGF-induced dimer formation. This was further supported by the fact 
that Pan-HER was found to completely block EGF binding to EGFR (Fig. 5A). However, it is important to 
notice that even though all three treatments effectively blocked EGF, only the EGFR targeting antibodies of 
Pan-HER resulted in single receptor and dimer degradation.  
In summary, the data presented here demonstrate superiority of the novel antibody mixture Pan-HER 
compared to single reference mAbs with regards to inhibition of proliferation, enhanced receptor 
degradation, and down-regulation of EGFR homo- and heterodimers with and without ligand stimulation. 
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The results imply that Pan-HER by these means will be able to overcome acquired resistance that cannot be 
sufficiently prevented by single targeting mAbs, whether the resistance mechanism is based on increased 
expression of HER-family receptor, switches in HER-family dependency and dimerization patterns, or 
increased ligand production. Our data support clinical evaluation of Pan-HER in patients with HER-family 
dependent epithelial tumors.
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Figure legends 
Figure 1. Detection of EGFR, HER2, and HER3 in 15 cancer cell lines by western blot analysis and flow 
cytometry using Quantum Simply Cellular beads. A. Total and surface expressed levels of EGFR, HER2, 
and HER3. β-actin was used as loading control for western blot analyses. B. Flow histograms and mean 
fluorescence intensity of EGFR, HER2, and HER3 surface expression in PK-1 and OVCAR-8 cells. Grey 
peaks are detections with isotype control antibodies.  
Figure 2. Pan-HER antibodies inhibit proliferation, down-regulate total receptor levels, and inhibit down-
stream signaling in PK-1 and OVCAR-8 cells. A. Cellular proliferation based on live cell imaging of PK-1 
and OVCAR-8 upon treatment with 50 µg/mL cetuximab, trastuzumab, pertuzumab, MM-121, HER-
targeting mAb mixture (EGFR, HER2, and HER3), Pan-HER or negative control antibody for 160 hours. 
Data represent means ± SEM (n = 6). Representative pictures showing percent confluency at t=160 hours of 
negative control mAb and Pan-HER treated cells. B. Protein levels of EGFR, HER2, HER3, AKT, pAKT 
(Ser473), ERK1/2, and pERK1/2 (Thr202/204) upon 24 hours of treatment with 50 µg/mL cetuximab, 
trastuzumab, pertuzumab, MM-121, mAb mixtures targeting EGFR, HER2 or HER3, and Pan-HER or 
negative control antibody as determined by western blot analyses. β-actin was used as loading control. 
Figure 3. Pan-HER down-regulates basal EGFR homodimer levels in PK-1 and OVCAR-8 cells. A. EGFR 
homodimers in PK-1 and representative pictures of negative control antibody, cetuximab, EGFR-targeting 
mAb mixture (EGFR) or Pan-HER treated cells. B. EGFR homodimers in OVCAR-8 and representative 
pictures of negative control antibody, cetuximab, EGFR-targeting mAb mixture (EGFR) or Pan-HER treated 
cells. EGFR homodimers were quantified upon 24 hours of antibody treatment at 40 µg/mL, measured as 
mean number of spots/cell in 15 pictures. Data represent means ± SD (n = 3). ***P < 0.001, **P < 0.01, *P < 
0.05. Top pictures: PLA signals shown in red and nuclei and cytosol in blue. The scaling is fixed to negative 
control pictures. Bottom pictures: Positive PLA signals included in quantification shown in colors and 
excluded PLA signals in white.  
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Figure 4. Pan-HER down-regulates basal EGFR heterodimer levels in PK-1 and OVCAR-8 cells. A. EGFR-
HER2 heterodimers in PK-1. B. EGFR-HER3 heterodimers in PK-1. C. EGFR-HER2 heterodimers in 
OVCAR-8. D. EGFR-HER3 heterodimers in OVCAR-8. EGFR-HER2 and EGFR-HER3 heterodimers were 
quantified upon 24 hours of treatment with 40 µg/mL cetuximab, trastuzumab, pertuzumab, MM-121, HER-
targeting mAb mixtures (EGFR, HER2, and HER3), Pan-HER or negative control antibody, measured as 
mean number of spots/cell in 15 pictures. Data represent means ± SD (n = 3). **P < 0.01, *P < 0.05.  
Figure 5. Pan-HER prevents EGF-induced changes in and activation of EGFR dimerization by blocking 
EGF in PK-1. A. Detection of EGF(red) and EGFR(green) +/- 30 minutes of treatment with 50ug/mL Pan-
HER followed by 3 minutes of stimulation with 2ug/mL Alexa 647-labelled EGF at 4°C using Opera high 
content screening system. Nuclei and cytosol are shown in blue and the color scaling is fixed to the untreated 
picture stimulated with EGF for 3 minutes. B. Basal and EGF-induced changes in EGFR homo- and EGFR-
HER2 heterodimer levels in PK-1 normalized to total EGFR levels. EGFR homo- and EGFR-HER2 
heterodimers were quantified upon 24 hours of treatment with 40 µg/mL cetuximab, trastuzumab, 
pertuzumab, MM-121, EGFR-targeting mAb mixture (EGFR), HER2-targeting mAb mixture (HER2), Pan-
HER or negative control antibody +/- 15 minutes of stimulation with 1 nM EGF, measured as mean number 
of spots/cell in 15 pictures using PLA. Data represent means ± SD (n = 3). ***P < 0.001, **P < 0.01. C. 
EGFR homo- and EGFR-HER2 heterodimer detection by Co-IP in PK-1 lysates upon 24 hour Pan-HER 
treatment +/- 15 minutes of stimulation with 1 nM EGF along with total receptor levels of EGFR and HER2 
as controls of equal amounts of EGFR and HER2 in IP samples and IP isotype control samples. D. Protein 
levels of EGFR, pEGFR (Tyr1068), AKT, pAKT (Ser473), ERK1/2, and pERK1/2 (Thr202/204) upon 24 
hours of treatment with 50 µg/mL Pan-HER or negative control antibody as determined by western blot 
analyses. β-actin was used as loading control. 
Supplementary Figure 1. Cell proliferation video of PK-1 and OVCAR-8 cells treated for 160 hours with 
50 µg/mL negative control mAb or Pan-HER using live imaging. The video is generated from 41 pictures 
taken at four hours intervals. 
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Supplementary Figure 2. Binding and cross-reactivity of the three detection antibodies (1260, 4385 and 
5259)  used in PLA, the six therapeutic Pan-HER antibodies (1277, 1565, 4384, 4517, 5038, and 5082), and 
the negative control antibody to recombinant EGFR (A), HER2 (B), and HER3 (C) measured as optical 
density (OD) by ELISA. 
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Detection of EGFR, HER2, and HER3 in 15 cancer cell lines by western blot analysis and flow cytometry using 
Quantum Simply Cellular beads. A. Total and surface expressed levels of EGFR, HER2, and HER3. β-actin 
was used as loading control for western blot analyses. B. Flow histograms and mean fluorescence intensity 
of EGFR, HER2, and HER3 surface expression in PK-1 and OVCAR-8 cells. Grey peaks are detections with 
isotype control antibodies.  
254x190mm (96 x 96 DPI)  
 
 
Page 26 of 30
John Wiley & Sons, Inc.
International Journal of Cancer
This article is protected by copyright. All rights reserved.
  
 
 
Pan-HER antibodies inhibit proliferation, down-regulate total receptor levels, and inhibit down-stream 
signaling in PK-1 and OVCAR-8 cells. A. Cellular proliferation based on live cell imaging of PK-1 and OVCAR-
8 upon treatment with 50 µg/mL cetuximab, trastuzumab, pertuzumab, MM-121, HER-targeting mAb 
mixture (EGFR, HER2, and HER3), Pan-HER or negative control antibody for 160 hours. Data represent 
mean ± SEM (n = 6). Representative pictures showing percent confluency at t=160 hours of negative 
control mAb and Pan-HER treated cells. B. Protein levels of EGFR, HER2, HER3, AKT, pAKT (Ser473), 
ERK1/2, and pERK1/2 (Thr202/204) upon 24 hours of treatment with 50 µg/mL cetuximab, trastuzumab, 
pertuzumab, MM-121, mAb mixtures targeting EGFR, HER2 or HER3, and Pan-HER or negative control 
antibody as determined by western blot analyses. β-actin was used as loading control.  
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Pan-HER down-regulates basal EGFR homodimer levels in PK-1 and OVCAR-8 cells. A. EGFR homodimers in 
PK-1 and representative pictures of negative control antibody, cetuximab, EGFR-targeting mAb mixture 
(EGFR) or Pan-HER treated cells. B. EGFR homodimers in OVCAR-8 and representative pictures of negative 
control antibody, cetuximab, EGFR-targeting mAb mixture (EGFR) or Pan-HER treated cells. EGFR 
homodimers were quantified upon 24 hours of antibody treatment at 40 µg/mL, measured as mean number 
of spots/cell in 15 pictures. Data represent mean ± SD (n = 3). ***P < 0.001, **P < 0.01, *P < 0.05. Top 
pictures: PLA signals shown in red and nuclei and cytosol in blue. The scaling is fixed to negative control 
pictures. Bottom pictures: Positive PLA signals included in quantification shown in colors and excluded PLA 
signals in white.  
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Pan-HER down-regulates basal EGFR heterodimer levels in PK-1 and OVCAR-8 cells. A. EGFR-HER2 
heterodimers in PK-1. B. EGFR-HER3 heterodimers in PK-1. C. EGFR-HER2 heterodimers in OVCAR-8. D. 
EGFR-HER3 heterodimers in OVCAR-8. EGFR-HER2 and EGFR-HER3 heterodimers were quantified upon 24 
hours of treatment with 40 µg/mL cetuximab, trastuzumab, pertuzumab, MM-121, HER-targeting mAb 
mixtures (EGFR, HER2, and HER3), Pan-HER or negative control antibody, measured as mean number of 
spots/cell in 15 pictures. Data represent mean ± SD (n = 3). **P < 0.01, *P < 0.05.  
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Pan-HER prevents EGF-induced changes in and activation of EGFR dimerization by blocking EGF in PK-1. A. 
Detection of EGF(red) and EGFR(green) +/- 30 minutes of treatment with 50ug/mL Pan-HER followed by 3 
minutes of stimulation with 2ug/mL Alexa 647-labelled EGF at 4°C using Opera high content screening 
system. Nuclei and cytosol are shown in blue and the color scaling is fixed to the untreated picture 
stimulated with EGF for 3 minutes. B. Basal and EGF-induced changes in EGFR homo- and EGFR-HER2 
heterodimer levels in PK-1 normalized to total EGFR levels. EGFR homo- and EGFR-HER2 heterodimers were 
quantified upon 24 hours of treatment with 40 µg/mL cetuximab, trastuzumab, pertuzumab, MM-121, EGFR-
targeting mAb mixture (EGFR), HER2-targeting mAb mixture (HER2), Pan-HER or negative control antibody 
+/- 15 minutes of stimulation with 1 nM EGF, measured as mean number of spots/cell in 15 pictures using 
PLA. Data represent means ± SD (n = 3). ***P < 0.001, **P < 0.01. BC. EGFR homo- and EGFR-HER2 
heterodimer detection by Co-IP in PK-1 lysates upon 24 hour Pan-HER treatment +/- 15 minutes of 
stimulation with 1 nM EGF along with total receptor levels of EGFR and HER2 as controls of equal amounts of 
EGFR and HER2 in IP samples and IP isotype control samples. CD. Protein levels of EGFR, pEGFR (Tyr1068), 
AKT, pAKT (Ser473), ERK1/2, and pERK1/2 (Thr202/204) upon 24 hours of treatment with 50 µg/mL Pan-
HER or negative control antibody as determined by western blot analyses. β-actin was used as loading 
control.  
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